Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CORT125236 in Healthy Subjects
NCT05003713Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Aug 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CORT125236 in Cushing syndrome and solid tumor (5 arms), sponsored by Corcept Therapeutics. Primary endpoint: Number of Participants with One or More Adverse Events at Day 19. Started Aug 2021; status: completed.
02
Drugs
CORT125236
03
Conditions
Cushing syndromesolid tumor
Beyond the preview
Go deeper on NCT05003713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003713.